EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

Lan Gao iD, Dieu Nguyen iD, Victoria White iD, Patricia M Livingston iD, Chan Y Cheah iD

European Journal of Haematology · 2026-12 · 117 (6) · 1541-1551

DOI: 10.1111/ejh.70286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 12.08.2026. Verfasst von Lan Gao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health, Deakin Health Economics, School of Health and Social Development, Institute for Health Transformation, Deakin University, Geelong,…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Health Care Costs, Cost of Illness. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Victorian Cancer Agency Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia.

Methods

A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in Australia under the CIT‐only era and the current era incorporating targeted therapies. The model considered treatment initiation, switching, and long‐term survival. Clinical inputs were derived from Australian Cancer Database data (2009–2020) for the CIT era, while cost and utility parameters were obtained from government sources and published literature. The model ran over a 15‐year horizon, reflecting the average age of CLL onset in Australia (68 years). Deterministic and probabilistic sensitivity analyses were performed.

Results

Total healthcare costs were substantially higher in the targeted therapy era ($751 727 per patient) compared to the CIT era ($33 505 per patient). Drug costs, particularly continuous BTKis therapy, were the main driver ($739 960 vs. $15 359). CLL patients were estimated to accumulate 3.62 and 7.83 QALYs in the CIT and targeted therapy eras, respectively, compared to 10.56 QALYs for the general population aged 68—indicating QALY losses of 6.94 and 2.73, respectively. Life expectancy shortfalls were 6.69 and 3.21 years, respectively. Targeted therapy led to incremental gains of 4.22 QALYs and 3.47 life years. Sensitivity analysis identified that discount rate, age at onset, treatment costs, and time horizon significantly influenced incremental costs, while treatment effectiveness and quality of life in the progression‐free state were key drivers of QALY gains.

Conclusions

CLL imposes a significant economic burden and QALY loss. While targeted therapies offer meaningful health gains, their high cost highlights the need for strategic planning to ensure sustainable resource allocation. Policymakers should balance clinical benefit with financial impact to optimise value in cancer care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellHealth Care CostsCost of IllnessHumansAustraliaAgedCost-Benefit AnalysisMolecular Targeted TherapyFemaleMaleMarkov ChainsMiddle AgedAged, 80 and overQuality-Adjusted Life Years

Stichwörter der Autor:innen

Bruton tyrosine kinase inhibitorsB‐cell lymphoma 2 (BCL‐2) inhibitorschronic lymphocytic leukaemiaeconomic coststargeted therapy

Autor:innen und Institutionen

  • Faculty of Health, Deakin Health Economics, School of Health and Social Development, Institute for Health Transformation, Deakin University, Geelong, Victoria, Australia.
  • Faculty of Health, School of Psychology, Deakin University, Geelong, Victoria, Australia.
  • Faculty of Health, Institute for Health Transformation, Deakin University, Geelong, Victoria, Australia.
  • Sir Charles Gairdner Hospital, University of Western Australia, Crawley, Western Australia, Australia.

ORCID-Profile: Lan Gao, Dieu Nguyen, Victoria White, Patricia M Livingston, Chan Y Cheah

Förderung

  • Victorian Cancer Agency Fellowship

Zitieren

APA

Gao, L., Nguyen, D., White, V., Livingston, P. M., & Cheah, C. Y. (2026). Economic Burden of Chronic Lymphocytic Leukaemia in Australia. European Journal of Haematology, 117(6), 1541-1551. https://doi.org/10.1111/ejh.70286

Vancouver

Gao L, Nguyen D, White V, Livingston PM, Cheah CY. Economic Burden of Chronic Lymphocytic Leukaemia in Australia. European Journal of Haematology. 2026;117(6):1541-1551. doi:10.1111/ejh.70286

BibTeX
@article{Gao2026,
  author = {Gao, Lan and Nguyen, Dieu and White, Victoria and Livingston, Patricia M and Cheah, Chan Y},
  title = {Economic Burden of Chronic Lymphocytic Leukaemia in Australia},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {6},
  pages = {1541--1551},
  doi = {10.1111/ejh.70286}
}
Kostenlos starten →